Akèy › Myelom Miltip › Ohio › Cleveland
Etid klinik pou Myelom Miltip nan Cleveland, OH
16 etid pou Myelom Miltip ap chèche patisipan nan sit nan ak bò kote Cleveland (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Ap rekriteFaz 3
- Research Site, Cleveland
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Ap rekriteFaz 2
- University Hospitals Cleveland Medical Center, Cleveland
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
Ap rekriteFaz 2
- Cleveland Clinic, Cleveland
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Ap rekriteFaz 3
- University Hospitals Cleveland Medical Center, Cleveland
- Cleveland Clinic Main Campus, Cleveland
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Ap rekriteFaz 3
- Cleveland Clinic, Cleveland
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 1/2
- Research Site, Cleveland
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Ap rekriteFaz 3
- Cleveland Clinic, Cleveland
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Ap rekriteFaz 3
- MetroHealth Medical Center, Cleveland
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Ap rekriteFaz 1
- Cleveland Clinic - Taussig Cancer Institute, Cleveland
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Ap rekriteFaz 3
- Research Site, Cleveland
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Ap rekriteFaz 3
- Seidman Cancer Center-University Hospitals Cleveland Medical Center, Cleveland
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
Ap rekriteEtid obsèvasyon
- University Hospitals Seidman Cancer Center, Cleveland
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Cleveland Clinic, Cleveland
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Ap rekriteFaz 1
- Cleveland Clinic, Cleveland
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Ap rekriteFaz 1/2
- University Hospitals Cleveland, Cleveland
LMY-920 for Treatment of Relapsed or Refractory Myeloma
Ap rekriteFaz 1
- University Hospitals Seidman Cancer Center, Cleveland
Etid Myelom Miltip nan lòt vil
- New York City, NY60 etid
- Boston, MA42 etid
- Atlanta, GA41 etid
- Houston, TX38 etid
- Durham, NC37 etid
- Nashville, TN32 etid
- Denver, CO27 etid
- Rochester, MN24 etid
- St. Louis, MO24 etid
- Columbus, OH24 etid
- Baldwin Park, CA23 etid
- Chicago, IL22 etid
Lòt etid nan Cleveland
- Kansè Poumon ki pa ti selil43 etid
- Kansè (tout kalite)36 etid
- Kansè nan tete35 etid
- Kansè pwostat34 etid
- Ensifizyans kadyak33 etid
- Kansè Metastatik30 etid
- Kansè ovè30 etid
- Kansè poumon26 etid
- Kansè kolorektal24 etid
- Maladi kadyovaskilè22 etid
- Kansè Endomèt20 etid
- Leksemi mieloïd egi20 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.